Control of lipolysis by natriuretic peptides and cyclic GMP

Trends in Endocrinology and Metabolism

Volumn 19, Issue 4, 2008, Pages 130-137

  Lafontan, Max ^a   Moro, Cédric ^a   Berlan, Michel ^a,b   Crampes, François ^a,b   Sengenes, Coralie ^a   Galitzky, Jean ^a  

^a INSERM   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BETA ADRENORECEPTOR ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; CATECHOLAMINE; CYCLIC AMP; CYCLIC GMP DEPENDENT PROTEIN KINASE;

ADIPOCYTE; EXERCISE; HUMAN; LIPID METABOLISM; LIPOLYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW;

ADIPOSE TISSUE; ANIMALS; BIOLOGICAL MARKERS; CYCLIC GMP; HUMANS; LIPOLYSIS; MODELS, BIOLOGICAL; NATRIURETIC PEPTIDES;

EID: 42949109612     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2007.11.006     Document Type: Review

References (72)

1. Langin D., and Arner P. Importance of TNFalpha and neutral lipases in human adipose tissue lipolysis. Trends Endocrinol. Metab. 17 (2006) 314-320
2. Despres J.P., and Lemieux I. Abdominal obesity and metabolic syndrome. Nature 444 (2006) 881-887
3. Bays H., et al. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J. Clin. Endocrinol. Metab. 89 (2004) 463-478
4. Langin D., and Lafontan M. Lipolysis and lipid mobilization in human adipose tissue. In: Bray G.A., and Bouchard C. (Eds). Handbook of Obesity. Etiology and Pathophysiology. 2nd edn (2004), Marcel Dekker 515-532
5. Horowitz J.F. Fatty acid mobilization from adipose tissue during exercise. Trends Endocrinol. Metab. 14 (2003) 386-392
6. Lee C.Y., and Burnett Jr. J.C. Natriuretic peptides and therapeutic applications. Heart Fail. Rev. 12 (2007) 131-142
7. Schirger J.A., et al. Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure. Mayo Clin. Proc. 74 (1999) 126-130
8. Munagala V.K., et al. The natriuretic peptides in cardiovascular medicine. Curr. Probl. Cardiol. 29 (2004) 707-769
9. Potter L.R., et al. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr. Rev. 27 (2006) 47-72
10. Sengenes C., et al. Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J. 14 (2000) 1345-1351
11. Moro C., et al. Phosphodiesterase-5A and neutral endopeptidase activities in human adipocytes do not control atrial natriuretic peptide-mediated lipolysis. Br. J. Pharmacol. 152 (2007) 1102-1110
12. Moro C., et al. Functional and pharmacological characterization of the natriuretic peptide-dependent lipolytic pathway in human fat cells. J. Pharmacol. Exp. Ther. 308 (2004) 984-992
13. Sengenes C., et al. Involvement of a cGMP-dependent pathway in natriuretic peptide-mediated hormone-sensitive lipase phosphorylation in human adipocytes. J. Biol. Chem. 278 (2003) 48617-48626
14. Sengenès C., et al. Natriuretic peptide-dependent lipolysis in fat cells is a primate specificity. Am. J. Physiol. Regul. Integr. Comp. Physiol. 283 (2002) R257-R265
15. Conti M., and Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu. Rev. Biochem. 76 (2007) 481-511
16. Moro C., et al. Differential regulation of atrial natriuretic peptide- and adrenergic receptor-dependent lipolytic pathways in human adipose tissue. Metabolism 54 (2005) 122-131
17. Zaccolo M., and Movsesian M.A. cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ. Res. 100 (2007) 1569-1578
18. Moro C., et al. Training enhances ANP lipid-mobilizing action in adipose tissue of overweight men. Med. Sci. Sports Exerc. 37 (2005) 1126-1132
19. Galitzky J., et al. The lipid mobilizing effect of atrial natriuretic peptides is unrelated to sympathetic nervous system activation or obesity in young men. J. Lipid Res. 42 (2001) 536-544
20. Birkenfeld A.L., et al. Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. J. Clin. Endocrinol. Metab. 90 (2005) 3622-3628
21. Birkenfeld A.L., et al. Beta-adrenergic and atrial natriuretic peptide interactions on human cardiovascular and metabolic regulation. J. Clin. Endocrinol. Metab. 91 (2006) 5069-5075
22. Anker S.D., et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 349 (1997) 1050-1053
23. Anker S. Cachexia and cardiology. Circulation 113 (2006) f53-f54
24. Moro C., et al. Atrial natriuretic peptide contributes to the physiological control of lipid mobilization in humans. FASEB J. 18 (2004) 908-910
25. Davis M.E., et al. Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation 113 (2006) 977-985
26. Berlin I., et al. Beta-adrenoceptor blockade potentiates acute exercise-induced release of atrial natriuretic peptide by increasing atrial diameter in normotensive healthy subjects. Eur. J. Clin. Pharmacol. 44 (1993) 127-133
27. Marie P.-Y., et al. Exercise release of cardiac natriuretic peptides is markedly enhanced when patients with coronary artery disease are treated medically by beta-blockers. J. Am. Coll. Cardiol. 43 (2004) 353-359
28. Jesek J.K., et al. Changes in plasma free fatty acids and glycerols during prolonged exercise in trained and hypertensive persons taking propranolol and pindolol. Am. J. Cardiol. 66 (1990) 1336-1341
29. Wijnen J.A., et al. Beta-blockade and lipolysis during endurance exercise. Eur. J. Clin. Pharmacol. 45 (1993) 101-105
30. Moro C., et al. Atrial natriuretic peptide contribution to lipid mobilization and utilization during head-down bed rest in humans. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293 (2007) R612-R617
31. Moro C., et al. Atrial natriuretic peptide stimulates lipid mobilization during repeated bouts of endurance exercise. Am. J. Physiol. Endocrinol. Metab. 290 (2006) E864-E869
32. König D., et al. Myocardial stress after competitive exercise in professional road cyclists. Med. Sci. Sports Exerc. 35 (2003) 1679-1683
33. Niessner A., et al. Increases in plasma levels of atrial and brain natriuretic peptides after running a marathon: are their effects partly counterbalanced by adrenocortical steroids?. Eur. J. Endocrinol. 149 (2003) 555-559
34. Moro C., et al. Sex differences in lipolysis-regulating mechanisms in overweight subjects: effect of exercise intensity. Obesity (Silver Spring) 15 (2007) 2245-2255
35. Sengenes C., et al. Increased lipolysis in adipose tissue and lipid mobilization to natriuretic peptides during low-calorie diet in obese women. Int. J. Obes. Relat. Metab. Disord. 26 (2002) 24-32
36. Sarzani R., et al. Fasting inhibits natriuretic peptides clearance receptor expression in rat adipose tissue. J. Hypertens. 13 (1995) 1241-1246
37. Wang T.J., et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 109 (2004) 594-600
38. Das S.R., et al. Impact of body mass and body composition on circulating levels of natriuretic peptides. Results From the Dallas Heart Study. Circulation 112 (2005) 2163-2168
39. Mehra M.R., et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J. Am. Coll. Cardiol. 43 (2004) 1590-1595
40. Dessi-Fulgheri P., et al. The natriuretic peptide system in obesity-related hypertension: new pathophysiological aspects. J. Nephrol. 11 (1998) 296-299
41. Giesler G., et al. The update on the rationale, use and selection of β-blockers in heart failure. Curr. Opin. Cardiol. 19 (2004) 250-253
42. Luchner A., et al. Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: Evidence from a population-based study. J. Am. Coll. Cardiol. 32 (1998) 1839-1844
43. Lommi J., et al. Heart failure ketosis. J. Intern. Med. 242 (1997) 231-238
44. Mokdad A.H., et al. Prevalence of obesity, diabetes and obesity-related health risk factor 2001. JAMA 289 (2003) 76-79
45. Jouven X., et al. Circulating nonesterified fatty acid level as a predictive risk factor for sudden death in population. Circulation 104 (2001) 756-761
46. Wang T.J., et al. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation 115 (2007) 1345-1353
47. Sarzani R., et al. Natriuretic peptide clearance receptor alleles and susceptibility to abdominal obesity. Obes. Res. 12 (2004) 351-356
48. Gardner D.G. Natriuretic peptides: markers or modulators of cardiac hypertrophy. Trends Endocrinol. Metab. 14 (2003) 411-416
49. Kalra P.R., and Tigas S. Regulation of lipolysis: natriuretic peptides and the development of cachexia. Int. J. Cardiol. 85 (2002) 125-132
50. Amato L., et al. Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. Diabetes Metab. 23 (1997) 213-218
51. Lommi J., et al. Free fatty acids kinetics and oxidation in congestive heart failure. Am. J. Cardiol. 81 (1998) 45-50
52. Anker S.D., et al. Cardiac cachexia. Ann. Med. 36 (2004) 518-529
53. Agustsson T., et al. Mechanism of increased lipolysis in cancer cachexia. Cancer Res. 67 (2007) 5531-5537
54. Lafontan M., et al. An unsuspected metabolic role for atrial natriuretic peptides: the control of lipolysis, lipid mobilization, and systemic nonesterified fatty acids levels in humans. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 2032-2042
55. Richards A.M., et al. BNP in hormone-guided treatment of heart failure. Trends Endocrinol. Metab. 13 (2002) 151-155
56. Maisel A.S. Nesiritide: a new therapy for the treatment of heart failure. Cardiovasc. Toxicol. 3 (2003) 37-42
57. Fain J.N., et al. Inhibition of leptin release by atrial natriuretic peptide (ANP) in human adipocytes. Biochem. Pharmacol. 65 (2003) 1883-1888
58. Moro C., et al. Atrial natriuretic peptide inhibits the production of adipokines and cytokines linked to inflammation and insulin resistance in human subcutaneous adipose tissue. Diabetologia 50 (2007) 1038-1047
59. Fruhbeck G., et al. Aquaporin-7 and glycerol permeability as novel obesity drug-target pathways. Trends Pharmacol. Sci. 27 (2006) 345-347
60. Lass A., et al. Adipose triglyceride lipase-mediated lipolysis of cellular fat stores is activated by CGI-58 and defective in Chanarin-Dorfman Syndrome. Cell Metab. 3 (2006) 309-319
61. Vollmar A.M. The role of atrial natriuretic peptide in the immune system. Peptides 26 (2005) 1086-1094
62. Schirmer H., and Omland T. Circulating N-terminal pro-atrial natriuretic peptide is an independent predictor of left ventricular hypertrophy in the general population. The Tromso Study. Eur. Heart J. 20 (1999) 755-763
63. Lerman A., et al. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left ventricular dysfunction. Lancet 341 (1993) 1105-1109
64. McDonagh T.A., et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 351 (1998) 9-13
65. Mukoyama M., et al. Increased human brain natriuretic peptide in congestive heart failure. N. Engl. J. Med. 323 (1990) 757-758
66. Cowie M.R., et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 350 (1997) 1349-1353
67. Yandle T.G., et al. Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. J. Clin. Endocrinol. Metab. 76 (1993) 832-838
68. La Villa G., et al. Plasma levels of brain natriuretic peptide in patients with cirrhosis. Hepatology 16 (1992) 156-161
69. Witthaut R., et al. Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med. 29 (2003) 1696-1702
70. Brueckmann M., et al. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation 112 (2005) 527-534
71. Kuhn M. Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A. Circ. Res. 93 (2003) 700-709
72. Anand-Srivastava M.B. Natriuretic peptide receptor-C signaling and regulation. Peptides 26 (2005) 1044-1059